Clinical trials
Major Depression Severe clinical trials
Below are recruiting major depression severe clinical trials, each written for real people, not researchers. We’re tracking 280 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06793397RecruitingPhase 3
Study of an experimental psychedelic-like drug for depression (CYB003)
This study tests an investigational medication (CYB003) for people with major depression whose current antidepressant isn't working well enough. It looks at whether this treatment can help improve depression symptoms.
Birmingham, AlabamaAges 18–85 - NCT06752759RecruitingPhase 3
Ketamine mist for depression
This trial tests if a ketamine mist you breathe in can help treat moderate to severe depression. It is for adults who are not helped enough by other treatments.
Brooklyn, New YorkAges 18–88 - NCT06692361Recruiting
Gut bacteria transplant for depression not helped by escitalopram
This trial tests whether transplanting healthy gut bacteria (fecal microbiota) can help people with depression that does not respond well to the antidepressant escitalopram. You will first take escitalopram for 2 weeks, and if it doesn't help enough, you may receive either the real transplant or a placebo capsule.
Wuhu, AnhuiAges 18–65 - NCT03646058RecruitingPhase 3
Add-on buprenorphine to ease suicidal thoughts in depression
This Phase 3 study tests whether adding buprenorphine to your usual pain-dose medicines can reduce severe suicidal thoughts during a major depressive episode. It may help people who are currently hospitalized or closely followed and have higher scores for both depression severity and suicidal thinking.
Bordeaux, FranceAges 18–65 - NCT06601140Recruiting
Testing a smartphone app for tracking depression symptoms
This study tests a smartphone-based emotional monitoring device (EMOCARE) to see if it can accurately measure your mood compared to a standard depression questionnaire. It may help researchers find a simpler way to track depression symptoms.
AgenAges 18 years+ - NCT06508710RecruitingPhase 3
Ketamine plus venlafaxine for severe depression
This trial tests whether adding ketamine to the antidepressant venlafaxine helps relieve severe depression faster than venlafaxine alone. If you are hospitalized for a serious depression and you meet safety criteria, you may be eligible.
Le Kremlin-Bicêtre, FranceAges 18–65 - NCT06523439Recruiting
Brain stimulation for depression in young people
This study tests a new type of brain stimulation called accelerated intermittent theta burst stimulation (aiTBS) in young people (ages 13-20) with depression who have not tried many treatments before. The goal is to see if this treatment can safely help reduce depression symptoms.
Austin, TexasAges 13–20 - NCT06396312Recruiting
Predicting lithium response in difficult depression
This study looks at how to predict which people with hard-to-treat depression will benefit from adding lithium to their antidepressant. If you have treatment-resistant depression and are considering lithium, this trial may help find the best treatment for you.
Munich, BavariaAges 18 years+ - NCT06384209Recruiting
Friendship Bench Plus for Depression
This study tests whether a structured talk therapy program called the Friendship Bench can help adults with moderate to severe depression. You will have conversations with trained lay counselors who guide you through problem-solving techniques.
HarareAges 18 years+ - NCT06086366Recruiting
Brain scan study for depression after COVID-19
This study uses brain scans to understand depression that starts soon after COVID-19. Researchers want to see if there are changes in brain chemistry related to depression, and you may help find new treatment targets.
Toronto, OntarioAges 18–75 - NCT05892744RecruitingPhase 4
Testing brain scans to help choose depression treatment
This trial studies how brain signals measured by MRI and EEG may help doctors choose the best treatment for depression. It focuses on people with early-onset, long-lasting or recurring major depression, and tests whether these “brain biomarkers” track with treatment choice and response.
Austin, TexasAges 18–65 - NCT05393622Recruiting
Brain stimulation trial for severe, treatment-resistant depression
This study tests an implanted form of brain stimulation for people with severe depression that has not improved with multiple medication trials. If you qualify, you would have brain scans and surgery planning, then follow a treatment-and-safety plan for several months.
Boston, MassachusettsAges 21–80 - NCT04004169Recruiting
Closed-loop deep brain stimulation for long-lasting depression
This study tests a special kind of brain stimulation that can adjust to your brain signals while treating major depression that has not improved with standard treatments. It may help people with severe, long-term treatment-resistant depression, but it requires brain surgery and frequent visits.
San Francisco, CaliforniaAges 22–70 - NCT05644301RecruitingPhase 3
Blood-marker guided add-on treatment for major depression
This study tests whether doctors can choose the best add-on immune-related treatment for people with major depressive disorder by using inflammation blood tests. It’s meant for people whose depression has not improved enough with their current antidepressant.
Duffel, AntwerpenAges 18–65 - NCT07691749Recruiting
Psychobiotics plus antidepressants for Major Depression
This study tests whether adding psychobiotics (special probiotics for mental health) to your current antidepressant helps treat major depression better than the antidepressant alone. It may be an option if you have moderate to severe depression and are on a stable antidepressant dose.
Lahore, Punjab ProvinceAges 18–60 - NCT07633080Recruiting
Magnesium supplement added to antidepressants for depression
This study tests whether adding magnesium bisglycinate (a mineral supplement) to your current antidepressant medication can help improve depression symptoms. Researchers want to see if this combination works better than antidepressant alone.
Bhubaneswar, OdishaAges 18–65 - NCT07523048RecruitingPhase 2
Dextromethorphan-Bupropion for Moderate-to-Severe Depression
This study tests a combination medication (dextromethorphan plus bupropion) to see how it affects brain activity in people with moderate-to-severe depression. Researchers use brain imaging (fMRI) to understand how the drug works and whether it may help relieve depression symptoms.
Toronto, OntarioAges 18–65 - NCT04637620RecruitingPhase 2
NMDA-based treatment study for major depression
This Phase 2 trial tests whether an NMDA-targeted treatment can improve symptoms of major depressive disorder (MDD). You may be able to join if your depression diagnosis and symptom score fit, and you meet several safety and study-following requirements.
TaichungAges 18–55 - NCT05136755RecruitingPhase 2
NMDA treatment for depression that did not improve
This trial studies an NMDA-based treatment for people with major depressive disorder who did not respond to at least one antidepressant. It may help by changing brain signaling linked to depression symptoms.
TaichungAges 18–65 - NCT05441969Recruiting
Brain stimulation study for major depression symptoms
This trial studies a way to change how excitable the brain is (through in-person brain stimulation) in people with major depression. It may help understand new treatments or symptom patterns that could be useful for major depression.
LisbonAges 18–65 - NCT05435222Recruiting
Male-only therapy program for major depression
This study tests a counseling/psychotherapy program designed specifically for men with major depression. If you qualify, you may be offered this structured therapy and followed to see whether it helps depressive symptoms.
Zurich, Canton of ZurichAges 25–50 - NCT07226661RecruitingPhase 2
Study of an investigational drug for depression
This trial tests an investigational medication for adults with major depressive disorder who are currently taking an antidepressant but still have symptoms. It aims to see if adding this new drug can improve mood better than a placebo.
Garden Grove, CaliforniaAges 18–70 - NCT07204314RecruitingPhase 3
Study of vortioxetine for teens with depression in Japan
This trial tests whether vortioxetine helps reduce symptoms of major depression in Japanese teenagers aged 12-17. It compares the study drug to a placebo to see if it is safe and effective.
Nagoya, Aichi-kenAges 12–17 - NCT07151846Enrolling by invitation
Using phone data to predict depression
This study uses your smartphone and a Fitbit to track mood patterns and see if they can predict depression. You may join as someone with a mood disorder, as a healthy volunteer, or as someone at higher risk for mood problems.
Seoul, Seongbuk-guAges 19–75
Hear when a new Major Depression Severe trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for major depression severe?
- Yes. Clin2 currently lists 280 recruiting major depression severe studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a major depression severe trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a major depression severe trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.